Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (25)

« Back to Publications

Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.

Bidel Z. et al, (2026), Eur Heart J, 47, 1649 - 1657

Blood Pressure Lowering and Risk of Cancer: Individual Participant-Level Data Meta-Analysis and Mendelian Randomization Studies.

Nazarzadeh M. et al, (2025), JACC CardioOncol, 7, 609 - 623

Efficacy of decentralised home-based antihypertensive treatment in older adults with multimorbidity and polypharmacy (ATEMPT): an open-label randomised controlled pilot trial.

Majert J. et al, (2024), Lancet Healthy Longev, 5, e172 - e181

Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis.

Bidel Z. et al, (2023), Hypertension, 80, 2293 - 2302

Stratification of diabetes in the context of comorbidities, using representation learning and topological data analysis.

Wamil M. et al, (2023), Sci Rep, 13

Blood pressure and risk of venous thromboembolism: a cohort analysis of 5.5 million UK adults and Mendelian randomization studies.

Nazarzadeh M. et al, (2023), Cardiovasc Res, 119, 835 - 842

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.

Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654

How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease in Patients With and Without Previous Cardiovascular Disease?

Canoy D. et al, (2022), Curr Cardiol Rep, 24, 851 - 860

The Blood Pressure Lowering Treatment Trialists' Collaboration: methodological clarifications of recent reports.

Nazarzadeh M. et al, (2022), J Hypertens, 40, 847 - 852

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.

Nazarzadeh M. et al, (2021), Lancet, 398, 1803 - 1810

Blood pressure treatment: how low should you go? - Authors' reply.

Rahimi K. et al, (2021), Lancet, 398, 1684 - 1685

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.

Blood Pressure Lowering Treatment Trialists' Collaboration ., (2021), Lancet, 398, 1053 - 1064

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual level meta-analysis of 145,000 randomized participants

CANOY D. et al, (2021), The Lancet

Reply: How low should you go?

CANOY D. et al, (2021), The Lancet

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.

Blood Pressure Lowering Treatment Trialists' Collaboration ., (2021), Lancet, 397, 1625 - 1636

Load More